Kiromic Biopharma, Inc. financial data

Symbol
KRBPQ, KRBP on OTC
Location
7707 Fannin St., Suite 140, Houston, TX
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 25.2 % +3.79%
Debt-to-equity -228 % +21.2%
Return On Equity 314 % +5.12%
Return On Assets -245 % -55.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.53M shares
Common Stock, Shares, Outstanding 1.53M shares +21.8%
Entity Public Float 3.38M USD +6.36%
Common Stock, Value, Issued 2K USD +100%
Weighted Average Number of Shares Outstanding, Basic 1.3M shares +49.5%
Weighted Average Number of Shares Outstanding, Diluted 1.3M shares +49.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 6.85M USD -1.35%
General and Administrative Expense 8.85M USD -14.2%
Operating Income (Loss) -23.8M USD -19.2%
Nonoperating Income (Expense) -832K USD -161%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -26.9M USD -28.4%
Earnings Per Share, Basic -7 USD/shares +86.8%
Earnings Per Share, Diluted -7 USD/shares +86.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.14M USD -64.5%
Assets, Current 3.3M USD -25.5%
Property, Plant and Equipment, Net 4.31M USD -30.2%
Operating Lease, Right-of-Use Asset 913K USD -40.8%
Other Assets, Noncurrent 21K USD 0%
Assets 8.55M USD -29.8%
Accounts Payable, Current 2.68M USD +25.3%
Employee-related Liabilities, Current 1.78M USD +106%
Liabilities, Current 20.9M USD +2.58%
Operating Lease, Liability, Noncurrent 228K USD -75%
Liabilities 21.1M USD -0.74%
Retained Earnings (Accumulated Deficit) -150M USD -21.9%
Stockholders' Equity Attributable to Parent -12.6M USD -38%
Liabilities and Equity 8.55M USD -29.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.7M USD -38.1%
Net Cash Provided by (Used in) Financing Activities 6.19M USD +11.8%
Net Cash Provided by (Used in) Investing Activities -21K USD
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 1.53M shares +21.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 472K USD -66.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.8M USD -44%
Interest Paid, Excluding Capitalized Interest, Operating Activities 5K USD -61.5%
Deferred Tax Assets, Valuation Allowance 28.5K USD +26.8%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 28.7K USD +25.9%
Operating Lease, Liability 913K USD -40.8%
Depreciation 2.23M USD +0.59%
Payments to Acquire Property, Plant, and Equipment 21K USD
Lessee, Operating Lease, Liability, to be Paid 968K USD -42.6%
Property, Plant and Equipment, Gross 11.5M USD +3.33%
Operating Lease, Liability, Current 685K USD +8.56%
Lessee, Operating Lease, Liability, to be Paid, Year Two 243K USD -66.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 725K USD +1.03%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 55K USD -61.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 243K USD -66.5%
Deferred Tax Assets, Operating Loss Carryforwards 19.5K USD +20.7%
Preferred Stock, Shares Issued 36.8K shares +163%
Preferred Stock, Shares Authorized 60M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 137M USD +20.6%
Preferred Stock, Shares Outstanding 36.8K shares +163%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%